Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Expenses: 2013-2025

Historic Operating Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $78.7 million.

  • Amphastar Pharmaceuticals' Operating Expenses rose 66.79% to $78.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.5 million, marking a year-over-year increase of 23.13%. This contributed to the annual value of $168.4 million for FY2024, which is 9.28% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Operating Expenses stood at $78.7 million, which was up 77.62% from $44.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Operating Expenses registered a high of $78.7 million during Q3 2025, and its lowest value of $26.4 million during Q3 2021.
  • Its 3-year average for Operating Expenses is $45.2 million, with a median of $42.1 million in 2024.
  • In the last 5 years, Amphastar Pharmaceuticals' Operating Expenses fell by 19.94% in 2021 and then surged by 66.79% in 2025.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Operating Expenses stood at $32.0 million in 2021, then climbed by 4.23% to $33.3 million in 2022, then rose by 26.47% to $42.2 million in 2023, then decreased by 1.56% to $41.5 million in 2024, then surged by 66.79% to $78.7 million in 2025.
  • Its Operating Expenses stands at $78.7 million for Q3 2025, versus $44.3 million for Q2 2025 and $48.0 million for Q1 2025.